EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The amyloid-beta wave hypothesis of Alzheimer’s disease

Sean J Miller, Robert Logan, Can Zhang, Brian P Hafler

Frontiers in Cellular and Infection Microbiology · 25.11.2025 · 15

DOI: 10.3389/fcimb.2025.1723095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 25.11.2025. Verfasst von Sean J Miller und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, United States. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Cure Alzheimer's Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is a complex and multifactorial disorder that affects all races and genders. Genetic traits influenced by lifestyle and environment lead to a tremendous amount of heterogeneity in Alzheimer’s disease onset and severity. Regardless of these unique contributing factors, Alzheimer’s disease is traditionally met with amyloid-beta plaque formation in the central nervous system. In this commentary, we shed light on the growing literature surrounding amyloid-beta’s ability to act as an antimicrobial peptide in the central nervous system’s innate immune response to pathogenic infections. We hypothesize that there are, “amyloid-beta waves” that are created by the responses of neuroglia and neurons to microbial pathogens. The improper clearance and residual buildup of amyloid-beta waves throughout life increases the likelihood of developing Alzheimer’s disease. In conclusion, we suggest that anti-amyloid therapies during pathogenic infections or flare-ups may slow the development of Alzheimer’s disease by reducing amyloid-beta waves throughout the aging of individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsHumansCentral Nervous SystemImmunity, InnateNeuronsPlaque, Amyloid

Stichwörter der Autor:innen

Alzheimer’s diseaseagingamyloid-betaantimicrobial peptideetiologymicrobial infections

Substanzen

Amyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, CT, United States.
  • The Alzheimer's Pathobiome Initiative, Wake Forest, NC, United States.
  • Department of Biology and Biotechnology, School of Science and Technology, Endicott College, Beverly, MA, United States.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, MassGeneral Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA…
  • Department of Pathology, Yale School of Medicine, New Haven, CT, United States.
  • The Broad Institute, Massachusetts Institute of Technology and Harvard, Cambridge, MA, United States.

Förderung

  • NEI NIH HHS
  • Cure Alzheimer's Fund

Zitieren

APA

Miller, S. J., Logan, R., Zhang, C., & Hafler, B. P. (2025). The amyloid-beta wave hypothesis of Alzheimer’s disease. Frontiers in Cellular and Infection Microbiology, 15. https://doi.org/10.3389/fcimb.2025.1723095

Vancouver

Miller SJ, Logan R, Zhang C, Hafler BP. The amyloid-beta wave hypothesis of Alzheimer’s disease. Frontiers in Cellular and Infection Microbiology. 2025;15. doi:10.3389/fcimb.2025.1723095

BibTeX
@article{Miller2025,
  author = {Miller, Sean J and Logan, Robert and Zhang, Can and Hafler, Brian P},
  title = {The amyloid-beta wave hypothesis of Alzheimer’s disease},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fcimb.2025.1723095}
}
Kostenlos starten →